Foundational studies demonstrate the requirement of LSD1 for clonogenic and leukemia stem cell potential of MLL-AF9 AML cells and LSD1 action at genomic loci bound by MLL-AF9 to sustain expression of AML-associated oncogenic programs which prevent apoptosis and differentiation [126]. The gene discussed is MLLT3; the disease is leukemia.